Efficacy of topical Bevacizumab in patients diagnosed with dry eye disease compared with conventional treatment

The Asia Research Center (ARC) by Chulalongkorn University0 个研究点目标入组 21 人开始时间: 2017年10月24日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1.Patients from outpatient department of the Department of Ophthalmology, King Chulalongkorn Memorial Hospital
•2.Patients diagnosed with dry eye disease aged 18 to 80 years old
•3.Slit lamp examination Tear Break-Up Time (SLETBUT) <= 5 seconds
•4.Patients who can regularly pay a visit as appointed

•1.Any structural abnormalities (such as eyelid trichiasis, entropion, and scarring)
•2.The presence of pinguecula or pterygium
•3.Active allergy or infection or inflammatory disease at the ocular surface unrelated to dry eye
•4.Any inflammation or active structural change in the iris or anterior chamber
•5.Glaucoma
•6.Diabetes or other systemic, dermatologic, or neurologic diseases that affect the health of ocular surface
•7.Use of any other topical medication other than artificial tears within the past month
•8.Use of any systemic anti-inflammatory drugs or medication that may interfere with tear production, such as anti-anxiety, anti-depressive, and anti-histamine medications within 3 months
•9.Previous punctal occlusion or eye surgery
•10.A positive history of refractive surgery or contact lens wear
•11.Hypertension that is unstable
•12.History of any Bevacizumab contraindications, such as heart failure, gastrointestinal perforation, and pregnancy.

发起方

The Asia Research Center (ARC) by Chulalongkorn University